Article Text

PDF
PS-044 Food and drug interactions in oral cancer therapy
  1. T Gramage Caro,
  2. E Delgado Silveira,
  3. N Vicente Oliveros,
  4. MI Muñoz Ojeda,
  5. T Bermejo Vicedo
  1. Hospital Ramón Y Cajal, Pharmacy, Madrid, Spain

Abstract

Background Determining the prevalence and seriousness of interactions with oral antineoplastic agents (OAA) is essential if we want to design efficient systems that could prevent them.

Purpose The aim of this study was to quantify and assess OAA-drug and OAA-food interactions in cancer patients.

Material and methods An observational, cohort study was conducted between June 2011 and May 2012 in the pharmacy outpatient department of a general hospital. 340 patients receiving OAA were interviewed by a pharmacist. Each one was followed-up for 6 months, through consecutive interviews. Clinical records and dispensing data were recorded: age, gender, tumour type, OAA treatment (active pharmaceutical ingredient and drug regimen), concomitant food intake and concomitant medication.

OAA-drug and OAA-food interactions and their relevance were assessed through Carcelero et al . (2014) application available from GEDEFO website (Oncology Pharmacy Spanish Group). Statistical data analysis was performed using STATA v.12 program.

Results 973 interviews were conducted. 104 (10.69%) OAA-drug interactions were detected, related to 47 (13.82%) patients (mean age 68.66 (53.12–76.92) years, 44.68% men, principal medical diagnoses: lung cancer (34.04%), colorectal cancer (21.28%) and chronic myeloid leukaemia (17.02%)). There were 2 (1–3) mean interactions per patient. 22 (21.15%) interactions were major and 94 (78.85%) were potential (requiring dose adjustment or close monitoring) according to their clinical relevance. 32 cases (3.28%) of food interactions with OAA were identified.

Identified drug interactions are shown in table 1.

Abstract PS-044 Table 1

Conclusion OAA-drug interactions occurred in 13% of cancer patients. More than 20% were major interactions. Fewer OAA-food interactions were identified. Implementing an individualised close monitoring programme for cancer patients that includes reviewing their whole treatment is essential as part of the pharmacist’s role in the outpatient department.

No conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.